Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
NEW YORK, March 02, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. (“Cardiovascular Systems”) (NASDAQ:CSII) between September 12, 2011 and January 21, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cardiovascular-systems.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cardiovascular-systems.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
